Literature DB >> 9456432

Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire.

S E Alters1, J R Gadea, M Sorich, G O'Donoghue, S Talib, R Philip.   

Abstract

The human carcinoembryonic antigen (CEA), which is expressed in several cancer types is a potential target for antigen-specific immunotherapy. In this study, we show that dendritic cells (DC) pulsed with an HLA class I restricted CEA cytotoxic T lymphocyte (CTL) peptide epitope can stimulate T cells to kill CEA peptide loaded T2 target cells as well as CEA expressing tumor lines in the presence of interleukin-7 (IL-7) in an HLA-restricted manner. This has been demonstrated for carcinoma patients as well as healthy donors. The DC-CEA + IL-7 stimulated cultures contained predominantly CD3+CD8+CD56- cells indicative of MHC class I restricted CTL. In addition, DC-CEA + IL-7 stimulated cells showed higher levels of CD69 expression compared with cells stimulated with IL-7 alone, implying an activated phenotype. When the T-cell receptor (TCR) from CTL cultures stimulated with DC-CEA + IL-7 was analyzed, an oligoclonal pattern of expression was found for certain V beta subfamilies compared with the polyclonal patterns shown by IL-7 or phytohemagglutinin stimulated T cells from the same donors. This TCR restriction appeared to be maintained and enhanced after additional rounds of restimulation with DC-CEA + IL-7. The association between cytotoxicity and TCR restriction suggests that TCR analysis may be useful as an in vitro indicator to monitor alterations in the T-cell population in response to antigen-specific immunotherapies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9456432     DOI: 10.1097/00002371-199801000-00002

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  4 in total

1.  Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas.

Authors:  An-hua Wu; Jing Xiao; Lars Anker; Walter A Hall; Dale S Gregerson; Webster K Cavenee; Wei Chen; Walter C Low
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

2.  Preparation of peptide-loaded dendritic cells for cancer immunotherapy.

Authors:  Michael A Morse; Tim Clay; Kirsten Colling; H Kim Lyerly
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

3.  Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens.

Authors:  N Okada; M Tsujino; Y Hagiwara; A Tada; Y Tamura; K Mori; T Saito; S Nakagawa; T Mayumi; T Fujita; A Yamamoto
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

4.  EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells.

Authors:  Yoo Jin Choi; Seong-Joon Park; You-Soo Park; Hee Sung Park; Kwang Mo Yang; Kyu Heo
Journal:  PLoS One       Date:  2018-01-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.